ProStrakan aims to double sales in two years.
ProStrakan, the Galashiels-based pharmaceutical company hopes to double their annual sales to £100m within two years. It has shown a 19% increase in revenues to £45.6m and is currently waiting for approvals on key products in the US and Europe.
Chief executive Wilson Totten said: "We are at a very important point in the company's history as we await our first US approval in the next few weeks and couple of pivotal European approvals. The question is how fast can we grow the company, not whether it's going to grow or not."
Earlier this month, the group reported that it receiving marketing authorisation in Sweden for Rapinyl (to be branded as Abstral in Sweden). Rapinyl is a fast-dissolving tablet for sub-lingual administration of fentanyl, intended for the treatment of breakthrough cancer pain for which ProStrakan has in-licensed exclusive rights in Europe from Orexo AB.
Sweden is the Reference Member State (RMS) for the wider EU Regulatory filing of Rapinyl and has taken the decision to issue a Marketing Authorisation for Sweden alone based on its Assessment Report made as RMS for the EU regulatory procedure.
ProStrakan currently has a wide portfolio of products in development and registration: * Rectogesic (pain associated with chronic anal fissure) - US * Tostran (hypogonadism) - US * Rapinyl (cancer breakthrough pain) - Registration, EU * Xomolix (post operative nausea and vomiting) - Registration, EU * Sancuso (chemotherapy induced nausea and vomiting) - Registration * Estradiol glucoside (HRT) - PII * Topical NO (onychomycosis) - PII * Topical anti- androgen (alopecia, acne) - PII * Testosterone glucoside (hypogonadism) - PI * TIMES 2 - Effect of transdermal testosterone replacement (Tostran) in hypogonadal men with either metabolic syndrome or type II diabetes mellitus - PIII.
Web:http://www.prostrakan.com/